This study is designed to examine the value of infusing BHB in type 1 diabetic subjects
during experimentally induced hypoglycemic episode in conjunction with testing of cognitive
function. This will lay the basis for subsequent trials exploring the novel use of
therapeutic doses of oral ketone formulations that are currently under commercial
development, which could serve as adjunct therapies to protect the brain from hypoglycemia in
type 1 diabetic subjects experiencing recurrent hypoglycemia.